Quest Diagnostics (DGX) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Quest Diagnostics Incorporated (DGX) insider buying and selling: no purchases, 26 sales
115 Form 4 Table I transactions filed with the SEC by Quest Diagnostics Incorporated insiders between 2025-08-25 and 2026-09-03 (15-month history): 0 open-market purchases and 26 sales, plus 89 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $10.6M by Davis J. E. on 2025-11-25.
Quest Diagnostics insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Quest Diagnostics insiders filed 22 sales worth $37.3M on the open market, and no purchases.
The biggest seller was Davis J. E. (CEO and President): $17.1M in 4 sales, out of 8 different sellers.
The largest trade of the period was a sale of $10.6M on Nov 25, 2025, by Davis J. E. (CEO and President), under a 10b5-1 plan. Form 4 on sec.gov (0001022079-25-000233).
Of the 22 sales, 19 (86%, $36.2M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 3 do not.
The last three months show 3 sales, against 2 in the three before. The latest sale from Sep 1, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Quest Diagnostics has more sales than 48 of the other 58, ranks 20 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with DGX's sales, largest first. The full history is in the tool above, already searched.
See all 115 DGX trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-11-25 | 2025-11-28 | Davis J. E. | CEO and President | $10.6M | S — Open-market sale (scheduled 10b5-1)4 Form 4 footnotesF1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 This transaction was executed in multiple trades at prices ranging from $190.810 to $191.805. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $191.820 to $192.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $192.820 to $193.310. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-08-28 | 2026-08-31 | Prevoznik Michael E | SVP & General Counsel | $5.5M | S — Open-market sale (scheduled 10b5-1)4 Form 4 footnotesF1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-13 | 2026-02-17 | Doherty Catherine T. | EVP, Regional Businesses | $5.4M | S — Open-market sale (scheduled 10b5-1)6 Form 4 footnotesF1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 This transaction was executed in multiple trades at prices ranging from $204.745 to $205.740. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $205.770 to $206.7489. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $206.770 to $207.675. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $207.810 to $208.600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $208.970 to $209.355. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2025-09-23 | 2025-09-25 | Prevoznik Michael E | SVP & General Counsel | $5.3M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 This transaction was executed in multiple trades at prices ranging from $187.000 to $187.880. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-09-01 | 2026-09-03 | Davis J. E. | CEO and President | $2.4M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
| 2026-03-02 | 2026-03-04 | Davis J. E. | CEO and President | $2.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF2 This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
| 2026-06-01 | 2026-06-02 | Davis J. E. | CEO and President | $1.9M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
| 2026-06-04 | 2026-06-08 | Kuppusamy Karthik | SVP, Clinical Solutions | $1.6M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. | SEC |
| 2025-11-18 | 2025-11-20 | Delaney Mark E | SVP & Chief Commercial Officer | $1.5M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
| 2026-02-10 | 2026-02-12 | Plewman Patrick | SVP for Diagnostic Services | $1.2M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
| 2026-03-05 | 2026-03-06 | Doherty Catherine T. | EVP, Regional Businesses | $1.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
| 2026-03-05 | 2026-03-06 | Prevoznik Michael E | SVP & General Counsel | $800k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
| 2026-03-05 | 2026-03-06 | Plewman Patrick | SVP for Diagnostic Services | $589k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
| 2026-03-04 | 2026-03-06 | Kuppusamy Karthik | SVP, Clinical Solutions | $538k | S — Open-market saleForm 4 footnoteF2 Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award. | SEC |
| 2026-07-28 | 2026-07-29 | Delaney Mark E | SVP & Chief Commercial Officer | $376k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
| 2025-08-21 | 2025-08-25 | Plewman Patrick | SVP for Diagnostic Services | $365k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
| 2026-02-19 | 2026-02-20 | Doherty Catherine T. | EVP, Regional Businesses | $294k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
| 2025-10-22 | 2025-10-24 | Pfeiffer Gary M | Director | $270k | S — Open-market sale | SEC |
| 2025-11-25 | 2025-11-28 | Gregg Vicky B | Director | $240k | S — Open-market sale | SEC |
| 2026-02-19 | 2026-02-20 | Prevoznik Michael E | SVP & General Counsel | $228k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Aug 25, 2025 and Sep 3, 2026 there is not one open-market purchase of Quest Diagnostics Incorporated: 26 sales worth $43.0M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Quest Diagnostics Incorporated's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| A | Grant or award | 39 | $21.3M |
| S | Open-market sale | 26 | $43.0M |
| F | Tax withholding (shares surrendered for taxes) | 24 | $14.9M |
| L | Small acquisition (Rule 16a-6) | 16 | $79k |
| M | Option exercise | 9 | $16.6M |
| G | Gift | 1 | $0 |
| Total | Everything filed in the period | 115 | $95.8M |
20 of the 115 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 18 distinct people or entities have filed Quest Diagnostics Incorporated transactions: none bought on the open market and 8 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 8 who sold on the open market (26 sales in all), the three biggest sellers account for $36.1M of the $43.0M: 84% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Davis J. E. | CEO and President | 11 | — | $17.1M (4) | 2026-09-03 |
| Prevoznik Michael E | SVP & General Counsel | 17 | — | $12.0M (7) | 2026-08-31 |
| Doherty Catherine T. | EVP, Regional Businesses | 10 | — | $7.0M (4) | 2026-03-06 |
| Plewman Patrick | SVP for Diagnostic Services | 15 | — | $2.4M (5) | 2026-07-27 |
| Kuppusamy Karthik | SVP, Clinical Solutions | 11 | — | $2.2M (2) | 2026-07-27 |
| Delaney Mark E | SVP & Chief Commercial Officer | 12 | — | $1.9M (2) | 2026-07-29 |
| Pfeiffer Gary M | Director | 2 | — | $270k (1) | 2026-05-21 |
| Gregg Vicky B | Director | 6 | — | $240k (1) | 2026-07-27 |
Shown here are the 8 who moved the most money, out of 18. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Mar 2026: 0 purchases and 8 sales, worth $5.5M. 5 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 1 | $365k |
| Sep 2025 | 0 | $0 | 3 | $5.4M |
| Oct 2025 | 0 | $0 | 1 | $270k |
| Nov 2025 | 0 | $0 | 3 | $12.3M |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 5 | $7.3M |
| Mar 2026 | 0 | $0 | 8 | $5.5M |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 0 | $0 |
| Jun 2026 | 0 | $0 | 2 | $3.6M |
| Jul 2026 | 0 | $0 | 1 | $376k |
| Aug 2026 | 0 | $0 | 1 | $5.5M |
| Sep 2026 | 0 | $0 | 1 | $2.4M |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Quest Diagnostics Incorporated (DGX) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
17 of the 20 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Quest Diagnostics has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Sep 3, 2026, and a Form 4 arrives up to two business days after the trade.
18 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.